The state of California sued Juul Labs Inc., alleging the e-cigarette maker engaged in a “systematic” and “wildly successful” campaign to attract teenagers to the San Francisco company’s nicotine devices.
Dublin, Ireland-based Alkermes is acquiring Boston-based Rodin Therapeutics for $100 million up front and up to $850 million in milestone payments.
BeiGene Ltd. priced the China-based drugmaker’s Brukinsa to treat a rare form of lymphoma at $12,935 for a 30-day supply.
Bristol-Myers Squibb Co. and Celgene Corp. won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla.
An Oklahoma judge said Johnson & Johnson must pay that state $465 million for fueling the opioid epidemic through the deceptive marketing of painkillers, down from his original award of $572 million.
A year after Bristol-Myers Squibb walked away from acquiring Promedior and the company’s fibrotic treatment portfolio, Roche stepped in to acquire the biotech firm for up to $1.4 billion.
Mylan has come under fire from the U.S. Food and Drug Administration over inadequate good manufacturing practices at one of the company’s drug manufacturing facilities in India.
Bayer and biotechnology company Dewpoint Therapeutics announced an option, research and license agreement worth up to $100 million.
Amgen filed a Worker Adjustment and Retraining (WARN) filing with the Commonwealth of Massachusetts, indicating the company planned to lay off 149 employees effective December 31, 2019.
Netherlands-based Kiadis Pharma is discontinuing Phase III development of lead T-cell asset ATIR101 and laying off half of the company’s staff, seven months after acquiring CytoSen.
